Trial Profile
Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Alveolar soft part sarcoma; Bladder cancer; Colorectal cancer; Fallopian tube cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 09 Nov 2021 Results published in the Clinical Cancer Research
- 19 Mar 2019 Status changed from active, no longer recruiting to completed.
- 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.